Biofrontera Inc. (NASDAQ:BFRI) Short Interest Update

Biofrontera Inc. (NASDAQ:BFRI) was the recipient of a significant decrease in short interest in January. As of January 30th, there was short interest totaling 141,320 shares, a decrease of 43.9% from the January 15th total of 251,788 shares. Currently, 1.3% of the shares of the stock are short sold. Based on an average trading volume of 108,670 shares, the days-to-cover ratio is presently 1.3 days. Based on an average trading volume of 108,670 shares, the days-to-cover ratio is presently 1.3 days. Currently, 1.3% of the shares of the stock are short sold.

Biofrontera Price Performance

Shares of Biofrontera stock opened at $0.79 on Friday. Biofrontera has a 1 year low of $0.54 and a 1 year high of $1.19. The business has a 50 day moving average price of $0.82 and a 200 day moving average price of $0.90. The company has a market capitalization of $9.20 million, a P/E ratio of -0.48 and a beta of 0.62.

Biofrontera (NASDAQ:BFRI) last released its quarterly earnings results on Wednesday, November 12th. The company reported ($0.59) earnings per share for the quarter, topping the consensus estimate of ($0.60) by $0.01. Biofrontera had a negative return on equity of 1,104.09% and a negative net margin of 47.28%.The company had revenue of $6.99 million during the quarter, compared to the consensus estimate of $7.00 million. As a group, research analysts expect that Biofrontera will post -3.01 EPS for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the company. Geode Capital Management LLC lifted its holdings in Biofrontera by 54.2% in the 4th quarter. Geode Capital Management LLC now owns 65,677 shares of the company’s stock valued at $37,000 after purchasing an additional 23,074 shares in the last quarter. AIGH Capital Management LLC grew its holdings in shares of Biofrontera by 33.1% during the second quarter. AIGH Capital Management LLC now owns 974,525 shares of the company’s stock worth $693,000 after buying an additional 242,370 shares in the last quarter. Finally, Rosalind Advisors Inc. raised its position in shares of Biofrontera by 51.5% in the second quarter. Rosalind Advisors Inc. now owns 976,448 shares of the company’s stock valued at $695,000 after buying an additional 332,055 shares during the last quarter. Institutional investors and hedge funds own 10.08% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently weighed in on BFRI shares. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Biofrontera in a research note on Thursday, October 30th. Benchmark reissued a “buy” rating on shares of Biofrontera in a report on Friday, November 14th. One equities research analyst has rated the stock with a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat, Biofrontera currently has an average rating of “Hold” and a consensus price target of $2.75.

Biofrontera Company Profile

Biofrontera AG is a specialty biopharmaceutical company focused on the research, development and commercialization of products for dermatological applications. The company’s core expertise lies in photodynamic therapy (PDT), a treatment modality that uses a photosensitizing agent activated by a specific light source to target diseased skin cells while sparing surrounding healthy tissue.

The flagship product in Biofrontera’s portfolio is Ameluz (aminolevulinic acid hydrochloride 10 % gel), which has received marketing approval in the European Union for treatment of actinic keratosis and basal cell carcinoma, and in the United States for actinic keratosis.